Recombined long-acting glucagons peptide analogue and preparation method thereof

A technology for glucagon and analogues, which is applied in the field of recombinant long-acting glucagon-like peptide analogues and their preparation, which can solve the problems of strong biological activity and long half-life, so as to improve curative effect, prolong half-life and relieve pain Effect

Active Publication Date: 2009-09-09
NOVOPROTEIN SCI INC
View PDF2 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But it is not a substrate of DIP-IV, so it has a longer half-life and stronger biological activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombined long-acting glucagons peptide analogue and preparation method thereof
  • Recombined long-acting glucagons peptide analogue and preparation method thereof
  • Recombined long-acting glucagons peptide analogue and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The construction of embodiment 1 genetically engineered bacteria

[0045] The exendin-4-HSA gene sequence was synthesized according to SEQ ID NO: 3, and the yeast codon was optimized. The methanolic yeast KEX2 restriction sequence KR and the xho1 restriction site were introduced into the N-terminal of the exendin-4 sequence, and the Not1 site was introduced into the C-terminal of the HAS. The synthesized fragment was double-digested with XhoI and NotI, and the vector pPICZαA plasmid was treated with XhoI and NotI double-digested at the same time, the fragments were recovered respectively, ligated and transformed into DH5α, and pPICZα-exendin-4-HSA transformants were screened. The correct pPICZα-exendin-4-HSA identified by sequencing was digested with sacI, electroporated to methanolic yeast X33, screened for zeocin resistance on YPD plate, and positive transformants were obtained. Pick a single colony, place it in a 250ml shake flask containing 25ml BMGY medium, and cu...

Embodiment 2

[0046] The cultivation and expression of embodiment 2 genetically engineered bacteria

[0047] Shake flask strain culture: 5 Erlenmeyer flasks with a capacity of 1L, each containing 200ml of YPD medium, the medium formula is 10g of yeast extract (1%), 20g of peptone (2%), and 20g of glucose (2%). Dissolve in deionized water and make up to 1L, steam sterilize at 115°C for 20 minutes. Each bottle was connected with 100 ul of the glycerol strain obtained in Example 1, and cultured on a shaker at 30° C. at 300 rpm for 24 hours. At this time, the bacterial concentration OD600 was between 6-20.

[0048] 30L tank fermentation culture: 30L automatic fermentation tank (Biostat c-dcu, Sartourius), specific operation can refer to its instruction manual. 15L of basal salt medium is filled in a 30L tank, and the formula is CaSO 4 2H 2 O 0.93g / l, K 2 SO 4 18.2g / l, MgSO 4 7H2O, KOH 4.13g / l, H 3 PO 4 26.7ml / l, 40g / l glycerin were dissolved in deionized water and adjusted to 15L. Co...

Embodiment 3

[0049] Example 3 Separation and Purification of Genetically Engineered Bacteria Expression Products

[0050] Blue dye affinity chromatography: adjust the pH of the fermentation supernatant obtained in Example 2 to 7.0 with 6M NaOH, and load it into blue dye affinity chromatography equilibrated with 20 mM phosphate at pH 7.0 and 500 mM NaCl buffer The column has a column bed diameter of 100 mm, a column bed height of 15 cm, and a column bed volume of 1000 ml. The flow rate is 8L / hour, and the sample is loaded after 3 hours. After loading the sample, first wash off unbound substances with 20 mM phosphate buffer at pH 7.0 and 128 mM KSCN buffer, and then wash off the fusion protein bound on the column with 20 mM phosphate buffer at pH 7.0 and 230 mM KSCN buffer. The protein peak was collected for detection by ultraviolet absorption at 280nM, and a total of 3200ml of the eluate was collected. Blue dye affinity chromatogram such as figure 2 shown

[0051] Hydrophobic chromatog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a recombined fusion protein, in particular discloses a recombined long-acting glucagons peptide analogue and a preparation method thereof. The long-acting glucagons peptide analogue is polypeptide by directly connecting duodenin analogue exendin-4 and human serum albumin, and no connecting peptide exists between the exendin-4 and the human serum albumin. The long-acting glucagons peptide analogue greatly prolongs the half-life of the exendin-4 and is clinically used to reduce the frequency of injection administration, lighten the suffering of patients, improve the curative effect and decrease the hospitalization cost.

Description

technical field [0001] The invention relates to a recombinant fusion protein, in particular to a recombinant long-acting glucagon-like peptide analog and a preparation method thereof. Background technique [0002] Diabetes is a metabolic disease with multiple etiologies and has become a major disease that seriously endangers human health and life in modern society. According to the data provided by the World Health Organization (WHO), the prevalence of diabetes in developed countries has reached as high as 5%-10%, and in my country it is about 3%. Among them, the number of type 2 diabetes patients currently accounts for more than 90% of all diabetes patients. [0003] Glucagon-like peptide-1 (glucagon.like peptide.1GLP-1) can bind to the GLP-1 receptor and control blood sugar through multiple actions, including stimulating insulin secretion, simultaneously inhibiting glucagon and gastric emptying , but will not produce hypoglycemia, and has a good effect on the treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N1/19C12P21/02C12R1/84
Inventor 朱化星蔡丽君王英明丁剑锋
Owner NOVOPROTEIN SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap